Related Experiment Video
Updated: Aug 13, 2026

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
Published on: March 14, 2014
Itraconazole-enhanced chemotherapy toxicity in a patient with Hodgkin lymphoma
Hamid Bashir1, Susannah Motl, Monika L Metzger
1Department of Internal Medicine, University of Tennessee Health Science Center, Memphis, 38105, USA.
Abstract:
The authors describe the clinical course of a boy with Hodgkin lymphoma who developed severe myelosuppression and neurotoxicity after the concurrent administration of vinblastine, doxorubicin, methotrexate, and prednisone chemotherapy (VAMP) and itraconazole. Several case reports have identified itraconazole-enhanced chemotherapy toxicity, especially in association with vinca alkaloid chemotherapy. This patient showed similar exacerbation of chemotherapy toxicity related to concurrent administration of itraconazole and vinblastine, doxorubicin, and methotrexate. Inpatient supportive management along with withdrawal of offending drugs resulted in the resolution of myelotoxic and neurotoxic manifestations. Hepatic cytochrome P450 enzyme inhibition and P-glycoprotein pump inhibitors are believed to interfere with the metabolism of several anticancer agents. Appropriate care should be exercised when combining cancer chemotherapy with cytochrome P450 and P-glycoprotein inhibitors, such as itraconazole.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Treatment Resistent Cancers
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Drug Toxicity: Risk factors
